Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02436707
Title Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors NCIC Clinical Trials Group
Indications

diffuse large B-cell lymphoma

B-cell lymphoma

Therapies

Ibrutinib

Cisplatin + Dexamethasone + Gemcitabine + Rituximab

Age Groups: adult
Covered Countries CAN

Facility Status City State Zip Country Details
Tom Baker Cancer Centre Recruiting Calgary Alberta T2N 4N2 Canada Details
Cross Cancer Institute Recruiting Edmonton Alberta T6G 1Z2 Canada Details
BCCA - Vancouver Cancer Centre Recruiting Vancouver British Columbia V5Z 4E6 Canada Details
CancerCare Manitoba Recruiting Winnipeg Manitoba R3E 0V9 Canada Details
The Moncton Hospital Suspended Moncton New Brunswick E1C 6Z8 Canada Details
QEII Health Sciences Centre Recruiting Halifax Nova Scotia B3H 1V7 Canada Details
Juravinski Cancer Centre at Hamilton Health Sciences Recruiting Hamilton Ontario L8V 5C2 Canada Details
Kingston Health Sciences Centre Recruiting Kingston Ontario K7L 2V7 Canada Details
Ottawa Hospital Research Institute Recruiting Ottawa Ontario K1H 8L6 Canada Details
Odette Cancer Centre Recruiting Toronto Ontario M4N 3M5 Canada Details
University Health Network Recruiting Toronto Ontario M5G 2M9 Canada Details
CIUSSS de l'Est-de-I'lle-de-Montreal Suspended Montreal Quebec H1T 2M4 Canada Details
CHUM-Centre Hospitalier de l'Universite de Montreal Recruiting Montreal Quebec H2X 3E4 Canada Details
CHU de Quebec-Hopital l'Enfant-Jesus (HEJ) Recruiting Quebec City Quebec G1J 1Z4 Canada Details
Allan Blair Cancer Centre Recruiting Regina Saskatchewan S4T 7T1 Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field